Guangxi Wuzhou Zhongheng Group Co Ltd Market Cap ($1.02 Billion)
Market Cap & Net Worth: Guangxi Wuzhou Zhongheng Group Co Ltd (600252)
Guangxi Wuzhou Zhongheng Group Co Ltd market cap. Guangxi Wuzhou Zhongheng Group Co Ltd (SHG:600252) has a market capitalization of $1.02 Billion (CN¥6.97 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #8501 globally and #1967 in its home market, demonstrating a -0.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangxi Wuzhou Zhongheng Group Co Ltd's stock price CN¥2.19 by its total outstanding shares 3184163070 (3.18 Billion). Also see 600252 cash generation efficiency for how efficiently the company converts equity into cash flow.
Guangxi Wuzhou Zhongheng Group Co Ltd Market Cap History (2015–2026)
Guangxi Wuzhou Zhongheng Group Co Ltd market cap history from 2015 to 2026. Data shows change from $3.07 Billion to $1.02 Billion (-6.27% CAGR). Check 600252 share price today for real-time trading data and today's change.
Guangxi Wuzhou Zhongheng Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangxi Wuzhou Zhongheng Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 600252 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.73x
Guangxi Wuzhou Zhongheng Group Co Ltd's market cap is 0.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.92 Billion | $1.67 Billion | $489.36 Million | 1.15x | 3.92x |
| 2017 | $1.86 Billion | $2.05 Billion | $604.91 Million | 0.91x | 3.07x |
| 2018 | $1.10 Billion | $3.30 Billion | $613.35 Million | 0.33x | 1.80x |
| 2019 | $1.43 Billion | $3.81 Billion | $744.95 Million | 0.37x | 1.92x |
| 2020 | $1.37 Billion | $3.68 Billion | $562.82 Million | 0.37x | 2.44x |
| 2021 | $1.77 Billion | $3.16 Billion | $306.92 Million | 0.56x | 5.78x |
| 2022 | $1.22 Billion | $2.71 Billion | $79.03 Million | 0.45x | 15.44x |
| 2023 | $1.17 Billion | $3.10 Billion | $84.31 Million | 0.38x | 13.87x |
| 2024 | $1.15 Billion | $2.27 Billion | -$376.98 Million | 0.50x | N/A |
| 2025 | $1.28 Billion | $1.75 Billion | -$357.09 Million | 0.73x | N/A |
Competitor Companies of 600252 by Market Capitalization
Companies near Guangxi Wuzhou Zhongheng Group Co Ltd in the global market cap rankings as of November 8, 2026. Also see Guangxi Wuzhou Zhongheng Group Co Ltd balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Guangxi Wuzhou Zhongheng Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Guangxi Wuzhou Zhongheng Group Co Ltd (2015–2026)
Market capitalization of Guangxi Wuzhou Zhongheng Group Co Ltd from 2015 to today. Between 2015 and today, Guangxi Wuzhou Zhongheng Group Co Ltd's market cap moved from $3.07 Billion to $ 1.02 Billion, with a yearly change of -6.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.02 Billion | -20.07% |
| 2025 | CN¥1.28 Billion | +11.38% |
| 2024 | CN¥1.15 Billion | -1.99% |
| 2023 | CN¥1.17 Billion | -4.18% |
| 2022 | CN¥1.22 Billion | -31.22% |
| 2021 | CN¥1.77 Billion | +29.39% |
| 2020 | CN¥1.37 Billion | -4.09% |
| 2019 | CN¥1.43 Billion | +29.44% |
| 2018 | CN¥1.10 Billion | -40.52% |
| 2017 | CN¥1.86 Billion | -3.09% |
| 2016 | CN¥1.92 Billion | -37.60% |
| 2015 | CN¥3.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Guangxi Wuzhou Zhongheng Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.02 Billion USD |
| MoneyControl | $1.02 Billion USD |
| MarketWatch | $1.02 Billion USD |
| marketcap.company | $1.02 Billion USD |
| Reuters | $1.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangxi Wuzhou Zhongheng Group Co Ltd
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for … Read more